Should bladder biopsies be performed routinely after bacillus Calmette-Guerin treatment for high-risk superficial transitional cell cancer of the bladder?

被引:20
作者
Guy, Laurent
Sauareux, Laurent
Molinie, Vincent
Botto, Henry
Boiteux, Jean-Paul
Lebret, Thierry
机构
[1] CHU, Hop G Montpied, Dept Urol, Serv Urol, F-63003 Clermont Ferrand, France
[2] Hop Foch, Dept Urol, Suresnes, France
关键词
bladder neoplasms; BCG vaccine; biopsy;
D O I
10.1016/j.eururo.2006.03.022
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: After endoscopic resection of high-grade superficial urothelial neoplasms (Ta, T1 or Tis), adjuvant bacillus Calmette-Guerin (BCG) therapy is performed routinely to avoid recurrence and/or progression. Vesical biopsies often are performed to assess the efficacy of treatment. The aim of our study was to evaluate the usefulness of these biopsies. Materials and methods: During this retrospective bi-centre study, 130 patients who had undergone vesical high-grade tumour resection were included. There were 40 Ta associated with Tis in three cases, 87 T1 associated with Tis in 13 cases, and three isolated Tis. After BCG treatment, the following parameters were studied: cytoscopic findings, urine cytology and the histologic results of systematised biopsies. Results: Urine cytology was positive (high-grade) for 26 patients and negative (normal or low-grade) for 104 patients. For the 26 patients with positive cytology, vesical flexible cystoscopy findings were considered suspicious in 18 patients and normal in eight patients. As for the 104 patients who presented negative cytology, cystoscopic findings were considered negative in 76 patients and suspicious in 28 patients. In the present study, the sensitivity of cytology and cystoscopy in the detection of recurrence after BCG treatment was 56% and 87.5%, respectively; specificity was 56% and 81.6%, respectively. When the two examinations were combined, sensitivity was 100%, and specificity was 76%. Conclusions: After BCG therapy, the association of negative flexible cystoscopy findings and normal urine cytology made it possible to avoid routine biopsies. Patients could therefore avoid the morbidity of this procedure. (c) 2006 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:516 / 520
页数:5
相关论文
共 28 条
[1]  
Bastacky S, 1999, CANCER CYTOPATHOL, V87, P118, DOI 10.1002/(SICI)1097-0142(19990625)87:3<118::AID-CNCR4>3.0.CO
[2]  
2-N
[3]   Is transurethral biopsy of the bladder necessary after 3 months to evaluate response to bacillus Calmette-Guerin therapy? [J].
Dalbagni, G ;
Rechtschaffen, T ;
Herr, HW .
JOURNAL OF UROLOGY, 1999, 162 (03) :708-709
[4]   The World Health Organization International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder [J].
Epstein, JI ;
Amin, MB ;
Reuter, VR ;
Mostofi, FK .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1998, 22 (12) :1435-1448
[5]   BACILLUS CALMETTE-GUERIN THERAPY ALTERS THE PROGRESSION OF SUPERFICIAL BLADDER-CANCER [J].
HERR, HW ;
LAUDONE, VP ;
BADALAMENT, RA ;
OETTGEN, HF ;
SOGANI, PC ;
FREEDMAN, BD ;
MELAMED, MR ;
WHITMORE, WF .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (09) :1450-1455
[6]   BACILLUS CALMETTE-GUERIN THERAPY FOR SUPERFICIAL BLADDER-CANCER - A 10-YEAR FOLLOW-UP [J].
HERR, HW ;
WARTINGER, DD ;
FAIR, WR ;
OETTGEN, HF .
JOURNAL OF UROLOGY, 1992, 147 (04) :1020-1023
[7]   Is bladder biopsy necessary at three or six months post BCG therapy? [J].
Highshaw, RA ;
Tanaka, ST ;
Evans, CP ;
White, RW .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2003, 21 (03) :207-209
[8]  
LAMM DL, 1992, UROL CLIN N AM, V19, P573
[9]   Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group study [J].
Lamm, DL ;
Blumenstein, BA ;
Crissman, JD ;
Montie, JE ;
Gottesman, JE ;
Lowe, BA ;
Sarosdy, MF ;
Bohl, RD ;
Grossman, HB ;
Beck, TM ;
Leimert, JT ;
Crawford, ED .
JOURNAL OF UROLOGY, 2000, 163 (04) :1124-1129
[10]   Preventing progression and improving survival with BCG maintenance [J].
Lamm, DL .
EUROPEAN UROLOGY, 2000, 37 :9-15